146 related articles for article (PubMed ID: 7616686)
1. Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.
Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
Jpn J Pharmacol; 1995 Feb; 67(2):117-24. PubMed ID: 7616686
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
[TBL] [Abstract][Full Text] [Related]
3. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
Akai T; Yamaguchi M; Mizuta E; Kuno S
Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
5. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
Kuno S
Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
[TBL] [Abstract][Full Text] [Related]
6. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
Vermeulen RJ; Drukarch B; Sahadat MC; Goosen C; Wolters EC; Stoof JC
Mov Disord; 1994 Nov; 9(6):664-72. PubMed ID: 7845408
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
Morissette M; Grondin R; Goulet M; Bédard PJ; Di Paolo T
J Neurochem; 1999 Feb; 72(2):682-92. PubMed ID: 9930741
[TBL] [Abstract][Full Text] [Related]
8. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
[TBL] [Abstract][Full Text] [Related]
9. Effect of D1 receptor stimulation in normal and MPTP monkeys.
Bédard PJ; Boucher R
Neurosci Lett; 1989 Sep; 104(1-2):223-8. PubMed ID: 2573015
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Graham WC; Sambrook MA; Crossman AR
Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
[TBL] [Abstract][Full Text] [Related]
11. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
12. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
13. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
Pollack AE; Yates TM
Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
[TBL] [Abstract][Full Text] [Related]
14. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
Luquin MR; Guillén J; Martínez-Vila E; Laguna J; Martínez-Lage JM
Eur J Pharmacol; 1994 Mar; 253(3):215-24. PubMed ID: 7911084
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
Blanchet PJ; Grondin R; Bédard PJ; Shiosaki K; Britton DR
Eur J Pharmacol; 1996 Aug; 309(1):13-20. PubMed ID: 8864687
[TBL] [Abstract][Full Text] [Related]
16. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content.
Calon F; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Neurochem Int; 1999 Jul; 35(1):81-91. PubMed ID: 10403433
[TBL] [Abstract][Full Text] [Related]
17. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
18. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Yoshimura N; Mizuta E; Kuno S; Sasa M; Yoshida O
Neuropharmacology; 1993 Apr; 32(4):315-21. PubMed ID: 8098860
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Elliott PJ; Walsh DM; Close SP
Neurosci Lett; 1992 Aug; 142(1):1-4. PubMed ID: 1357609
[TBL] [Abstract][Full Text] [Related]
20. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
Weick BG; Walters JR
Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]